ArticleChembiochem : a European journal of chemical biology2026
Accessing New Phenanthroline-Oxazine Scaffolds as Copper-Dependent DNA Damaging Probes.
Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rational design of an acridine-derived click chemistry-based artificial metallo-nuclease.RSC chemical biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
1,10-Phenanthroline (phen) is a versatile ligand commonly used in coordination chemistry, with particular interest in its ability to promote DNA binding and damage when coordinated with transition metals. Structural modifications of phen modulate the recognition and reactivity of the associated complexes at the nucleic acid interface. A promising new modification of phen stems from the incorporation of amino acid derivatives at the 5- and 6-positions leading to phenanthroline-oxazine scaffolds, which improve the pharmacokinetic and pharmacodynamic properties of resultant complexes. However, a limited number of phenanthroline-oxazine (PO) scaffolds have been reported and accessing new natural amino acid derivatives has, thus far, been synthetically intractable. Herein, we advance the synthetic conditions required for accessing new POs. We identified the type of amino acid substrate coupled with solvent selection and reaction temperature were the main influencing parameters for accessing new PO scaffolds. In total, eleven new PO ligands were successfully synthesized, purified, and characterized. The new scaffolds were then examined for their Cu-dependent DNA binding and damaging profiles and we correlate structure-activity relationships to specific PO modifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.